Please use this identifier to cite or link to this item:
Title: Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug
Authors: Gan, Hanjie Jonathan
Harikishore, Amaravadhi
Lee, Jihye
Jeon, Sangeun
Rajan, Sreekanth
Chen, Ming Wei
Neo, Jun Long
Kim, Seungtaek
Yoon, Ho Sup
Keywords: Science::Biological sciences
Issue Date: 2021
Source: Gan, H. J., Harikishore, A., Lee, J., Jeon, S., Rajan, S., Chen, M. W., Neo, J. L., Kim, S. & Yoon, H. S. (2021). Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug. Antiviral Research, 185, 104996-.
Project: NRF2017M3A9G6068245
Journal: Antiviral Research
Abstract: Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for this disease. Available treatments are either supportive medications in use for other diseases or those lacking specificity requiring higher doses. The viral infection mode is initiated by the attachment of the viral spike glycoprotein to the human Dipeptidyl Peptidase IV (DPP4). Our attempts to screen antivirals against MERS led us to identify montelukast sodium hydrate (MSH), an FDA-approved anti-asthma drug, as an agent attenuating MERS-CoV infection. We showed that MSH directly binds to MERS-CoV-Receptor-Binding Domain (RBD) and inhibits its molecular interaction with DPP4 in a dose-dependent manner. Our cell-based inhibition assays using MERS pseudovirions demonstrated that viral infection was significantly inhibited by MSH and was further validated using infectious MERS-CoV culture. Thus, we propose MSH as a potential candidate for therapeutic developments against MERS-CoV infections.
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2020.104996
Schools: School of Biological Sciences 
Rights: © 2020 Elsevier B.V. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SBS Journal Articles

Citations 50

Updated on Sep 24, 2023

Web of ScienceTM
Citations 50

Updated on Sep 27, 2023

Page view(s)

Updated on Sep 28, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.